A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Bruce E. Johnson, Mark G. Kris, Lynne D Berry, David J. Kwiatkowski, Anthony John Iafrate, Marileila Varella-Garcia, Ignacio Ivan Wistuba, Wilbur A. Franklin, Marc Ladanyi, Pei-Fang Su, Lecia V. Sequist, Fadlo Raja Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Giuseppe Giaccone, John D. Minna, Paul A. Bunn
Institutions: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Vanderbilt University, Harvard University, Massachusetts General Hospital, University of Colorado Anschutz, University of Colorado Denver, The University of Texas MD Anderson Cancer Center, Vanderbilt-Ingram Cancer Center, Emory University, Winship Cancer Institute, University of California, Los Angeles, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Moffitt Cancer Center, National Institutes of Health, National Cancer Institute, University of Colorado Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W70527475